These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 17618313)

  • 1. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.
    Barrett MP; Boykin DW; Brun R; Tidwell RR
    Br J Pharmacol; 2007 Dec; 152(8):1155-71. PubMed ID: 17618313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diamidines for human African trypanosomiasis.
    Paine MF; Wang MZ; Generaux CN; Boykin DW; Wilson WD; De Koning HP; Olson CA; Pohlig G; Burri C; Brun R; Murilla GA; Thuita JK; Barrett MP; Tidwell RR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):876-83. PubMed ID: 20721830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.
    Nok AJ
    Parasitol Res; 2003 May; 90(1):71-9. PubMed ID: 12743807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy of human African trypanosomiasis.
    Burchmore RJ; Ogbunude PO; Enanga B; Barrett MP
    Curr Pharm Des; 2002; 8(4):256-67. PubMed ID: 11860365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy against human African trypanosomiasis: is there a road to success?
    Burri C
    Parasitology; 2010 Dec; 137(14):1987-94. PubMed ID: 20961469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
    Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Characterization of FTY720 for the Treatment of Human African Trypanosomiasis.
    Jones AJ; Kaiser M; Avery VM
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1859-61. PubMed ID: 26666915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of antihuman African trypanosomiasis drugs across the blood-brain and blood-CSF barriers.
    Sekhar GN; Watson CP; Fidanboylu M; Sanderson L; Thomas SA
    Adv Pharmacol; 2014; 71():245-75. PubMed ID: 25307219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The continuing problem of human African trypanosomiasis (sleeping sickness).
    Kennedy PG
    Ann Neurol; 2008 Aug; 64(2):116-26. PubMed ID: 18756506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control and surveillance of human African trypanosomiasis.
    World Health Organization
    World Health Organ Tech Rep Ser; 2013; (984):1-237. PubMed ID: 24552089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment perspectives for human African trypanosomiasis.
    Bouteille B; Oukem O; Bisser S; Dumas M
    Fundam Clin Pharmacol; 2003 Apr; 17(2):171-81. PubMed ID: 12667227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter.
    Gilbert IH
    Parasitology; 2014 Jan; 141(1):28-36. PubMed ID: 23931634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
    Wenzler T; Boykin DW; Ismail MA; Hall JE; Tidwell RR; Brun R
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4185-92. PubMed ID: 19620327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Human African trypanosomiasis].
    Dumas M; Bouteille B
    C R Seances Soc Biol Fil; 1996; 190(4):395-408. PubMed ID: 8952890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
    Gehrig S; Efferth T
    Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sleep structure: a new diagnostic tool for stage determination in sleeping sickness.
    Buguet A; Bisser S; Josenando T; Chapotot F; Cespuglio R
    Acta Trop; 2005 Jan; 93(1):107-17. PubMed ID: 15589803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eflornithine for the treatment of human African trypanosomiasis.
    Burri C; Brun R
    Parasitol Res; 2003 Jun; 90 Supp 1():S49-52. PubMed ID: 12811548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei.
    Hiltensperger G; Jones NG; Niedermeier S; Stich A; Kaiser M; Jung J; Puhl S; Damme A; Braunschweig H; Meinel L; Engstler M; Holzgrabe U
    J Med Chem; 2012 Mar; 55(6):2538-48. PubMed ID: 22376072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug.
    Sanderson L; da Silva M; Sekhar GN; Brown RC; Burrell-Saward H; Fidanboylu M; Liu B; Dailey LA; Dreiss CA; Lorenz C; Christie M; Persaud SJ; Yardley V; Croft SL; Valero M; Thomas SA
    PLoS Negl Trop Dis; 2021 Apr; 15(4):e0009276. PubMed ID: 33857146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Veterinary link to drug resistance in human African trypanosomiasis?
    Barrett MP
    Lancet; 2001 Aug; 358(9282):603-4. PubMed ID: 11530144
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.